What’s next for GLP-1 therapies? Our Vice President of Medical Affairs, Dr. Judith Hey-Hadavi, joined LCGC International‘s Peer Exchange panel to highlight the critical link between analytical science and clinical trials practice in advancing these treatments.
Check out the full video series to explore the future of GLP-1 therapies, including the shift from protein-based therapies to small molecule options, factors shaping patient education, dosing and safety, and emerging opportunities beyond diabetes and obesity. Watch it here.
